… antiphospholipid syndrome (APS). The standard anticoagulant treatment for thrombotic APS
is life… or who experience recurrent VTE while on apparently therapeutic VKA anticoagulation. …

Antiphospholipid antibody syndrome (APS) requires long-term anticoagulation to prevent
recurrent thrombosis. Direct oral anticoagulants (DOACs) have been increasingly used in APS …

… of phospholipids, phospholipid-binding proteins, or both. The term “antiphospholipid syndrome”
… association between antiphospholipid antibodies and a syndrome of hypercoagulability. …

… antibody–related vascular events range from a superficial thrombosis to life-threatening …
Based on our retrospective experience with eight patients, there was no recurrence in three …

… inhibit the anticoagulant effect of phospholipid oxidation.… Current status and implications
of autoimmune antiphospholipid … Antiphospholipid antibodies are directed against a complex …

… learn about their experiences of Antiphospholipid syndrome. I gratefully acknowledge the …
in patients with Antiphospholipid syndrome (APS) in the context of quality of life as an indicator …

… Primary antiphospholipid syndrome (PAPS) is a chronic autoimmune disorder clinically
characterized by thromboembolic events or obstetric complications. Prolonged anticoagulation …

… Belimumab was not studied for preventing thrombosis and other aPL manifestations in
SLE patients with aPL, but with the increasing experience we expect to learn more about its …

… , scientists, and investigators from around the world interested in APS research. The founding
… may differ for patients with aPL who experience initial venous or arterial thrombotic events, …

… aspirin to be recommended for patients who experience recurrent events while receiving oral
… for once-daily administration because of better bioavailability and longer half-life, and may …